Profile for Exelixis, Inc. (EXEL)
« Back to company indexEXEL Chatter Timeline
Stock Ticker for EXEL
Most Active Tweeters for EXEL
| User | Tweets |
|---|---|
| @TickerReport | 16 |
| @SleekMoneycom | 16 |
| @intercooleronli | 15 |
| @CFinancialNews | 14 |
| @chaffeybreeze | 12 |
Recent Tweets for EXEL
 |
@TheMarketsDaily Brokerages Set Exelixis, Inc. $EXEL Price Target at $26.51 https://t.co/RyUAPds1uO September 25th 2017, 5:09pm |
 |
@AlpacaAlerts $EXEL red today w/ 11 ? signals like three inside down. Sup/Res=23.06/23.65. Wanna short? https://t.co/Kb9PahiuSe https://t.co/0k04qjIj9p September 25th 2017, 4:09pm |
 |
@1MinuteStock We calculated 21-day Expected Return of $EXEL for you: -7.24% https://t.co/46E2WrBpDC September 25th 2017, 4:09pm |
 |
@CFinancialNews Oppenheimer Holdings, Inc. Reiterates “Hold” Rating for Exelixis, Inc. $EXEL https://t.co/GlEmHw1lJY September 25th 2017, 4:09pm |
 |
@intercooleronli Oppenheimer Holdings, Inc. Reiterates “Hold” Rating for Exelixis, Inc. $EXEL https://t.co/udWFdbKCK2 September 25th 2017, 4:09pm |
 |
@MaisaCorp $EXEL Daiichi Sankyo said that it intends to submit a Japanese regulatory application for esaxerenone for an essential hypertension September 25th 2017, 4:09pm |
|
@MaisaCorp $EXEL Daiichi Sankyo's Trial for Hypertension Treatment Esaxerenone Meets Primary Endpoint September 25th 2017, 4:09pm |
 |
@SwingTradeBot Recent $EXEL technical alerts: Fell Below 50 DMA plus 8 more alerts... https://t.co/R8mMMMOolt September 25th 2017, 3:09pm |
 |
@kjilly Boost for $EXEL as partner Daiichi Sankyo cues up #hypertension drug filing #FDA #highbloodpressure #biotech #pharma https://t.co/dCMErXnEIB September 25th 2017, 1:09pm |
 |
@stockboardinc $EXEL Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxereno... - https://t.co/VBRJs6BaDG September 25th 2017, 12:09pm |
 |
@dakotafinancial OxFORD Asset Management LLP Acquires New Stake in Exelixis, Inc. $EXEL https://t.co/673jweFf2G September 25th 2017, 11:09am |
 |
@leahanneta 10:45 ET Volume Leader #69 - EXEL 1,546,349 Exelixis Inc $EXEL 24.04 -0.43 -1.76% High today of 25.10 day low https://t.co/siPNeiiEQj September 25th 2017, 11:09am |
 |
@StockGodd @timeout2575 $EXEL what were you saying... lol https://t.co/U9HEeErPKK September 25th 2017, 10:09am |
 |
@brockthornhill RT @mikegoodma: Esaxerenone achieves P3 primary endpt in hypertension. $EXEL in line for ~$150m in MS from Daiichi plus royalties. https://… September 25th 2017, 9:09am |
 |
@rosderek @mikegoodma & initiated P3 of CS-3150 in pts w/ diabetic nephropathy. Can't recall CS-3150 in any PT or valuation model for $EXEL September 25th 2017, 9:09am |
 |
@mikegoodma Esaxerenone achieves P3 primary endpt in hypertension. $EXEL in line for ~$150m in MS from Daiichi plus royalties. https://t.co/qMKHszsoPM September 25th 2017, 9:09am |
 |
@TopFiveTraders RT AlertTrade "#SwingTradeAlert $EXEL technical alerts: Expansion Pivot Sell Setup, MACD Bearish… … https://t.co/Dg30cCgKLl" September 25th 2017, 8:09am |
|
@SwingTradeBot $EXEL technical alerts: Expansion Pivot Sell Setup, MACD Bearish Signal Line Cross, Expansion Bre... https://t.co/R8mMMMOolt September 25th 2017, 8:09am |
 |
@fvwhh14 @timeout2575 $EXEL anyone knows terms for milestones & royalties? September 25th 2017, 8:09am |
 |
@deepxdive $EXEL Exelixis, Inc. breached its 50 day moving average in a Bearish Manner EXEL-US September 25, 2017… https://t.co/qbfbA4ckCl September 25th 2017, 8:09am |
 |
@ITRADEVOL $EXEL Price & Volume Summary https://t.co/zU3FTBlY8A September 25th 2017, 8:09am |
 |
@wilkinson991 $EXEL The finances and #chart are really pretty damn nice. Not much wrong here. No position and no idea what w happ… https://t.co/bb8CWdoQTP September 25th 2017, 7:09am |
|
@wilkinson991 $EXEL Not in it anymore but sure wud like to see this one get itself straightened out. Always liked their finances here. #stocks #tradeideas September 25th 2017, 7:09am |
 |
@wosaikeneriki Meditor Group LTD Lifted Its Exelixis $EXEL Stake by $25.10 Million as Share Price Declined ... September 25th 2017, 7:09am |
 |
@mgutierrez_apex $EXEL ESAX-HTN pivotal study in essential hypertension met primary objective; filing in Japan planned for Q1 2018 September 25th 2017, 6:09am |
 |
@timeout2575 $EXEL I thought they were only in oncology! What a pleasant surprise! https://t.co/CBvxJPWWWU September 25th 2017, 6:09am |
 |
@Briefingcom $EXEL: Exelixis reports ESAX-HTN pivotal study in essential hypertension met primary objective https://t.co/n62nBkxHdQ September 25th 2017, 5:09am |
 |
@stocknewsdotcom $EXEL Reports ESAX-HTN pivotal study in essential hypertension met primary objective https://t.co/EkmZdPKRa7 September 25th 2017, 5:09am |
|
@1MinuteStock Unicorn Bay rating for $EXEL is 2.84 out of 5. https://t.co/Lw8PCl4AEv September 25th 2017, 5:09am |
 |
@IRAMarketReport Exelixis, Inc. $EXEL Cut to Market Perform at Leerink Swann https://t.co/IkEUTscamN September 25th 2017, 3:09am |
 |
@chaffeybreeze Exelixis, Inc. $EXEL Cut to Market Perform at Leerink Swann https://t.co/Q4HU4395Rt September 25th 2017, 3:09am |
|
@CFinancialNews Exelixis, Inc. $EXEL to Post Q3 2017 Earnings of $0.08 Per Share, Leerink Swann Forecasts https://t.co/Mg0jPLeJEl September 25th 2017, 2:09am |
|
@TheMarketsDaily Exelixis, Inc. $EXEL to Post Q3 2017 Earnings of $0.08 Per Share, Leerink Swann Forecasts https://t.co/ngypAqtfzN September 25th 2017, 2:09am |
|
@intercooleronli Exelixis, Inc. $EXEL to Post Q3 2017 Earnings of $0.08 Per Share, Leerink Swann Forecasts https://t.co/6x2pkaPJhW September 25th 2017, 2:09am |
|
@StockGodd $EXEL If pre market price can retest my overhead resistance level 24.67 & fail I'll look to short it to next pivot… https://t.co/B42JWqvaNb September 25th 2017, 12:09am |
 |
@realmaciej RT @bradloncar: Filed under the category of things I didn't know. $EXEL has a hypertension program with Daiichi Sankyo. September 24th 2017, 11:09pm |
 |
@recervan RT @odibro: $EXEL Update on Collaborator Daiichi ‘s P3 Clinical Progress with Esaxerenone (CS-3150), Including Top line results https://t.… September 24th 2017, 10:09pm |
 |
@IncredibleTrade $EXEL Provides Update on Collaborator Daiichi Sankyo's Ph3 Clinical Progress with Esaxerenone (CS-3150) --- https://t.co/a8DmvQhT2t September 24th 2017, 9:09pm |
 |
@ExelixisInc Our partner @DaiichiSankyo reported positive top-line results from a ph. 3 trial in essential hypertension. https://t.co/xEYoBbcLgg $EXEL September 24th 2017, 9:09pm |
 |
@bradloncar Filed under the category of things I didn't know. $EXEL has a hypertension program with Daiichi Sankyo. September 24th 2017, 9:09pm |
 |
@odibro $EXEL Update on Collaborator Daiichi ‘s P3 Clinical Progress with Esaxerenone (CS-3150), Including Top line results https://t.co/Ot3RdsV4qP September 24th 2017, 9:09pm |
 |
@Allstocknews $EXEL Exelixis Provides Update on Collaborator Daiichi Sankyo's Phase 3 Clinical Progress with Esaxerenone (C From our Stock News Alerts App September 24th 2017, 9:09pm |
 |
@newswithvalue $EXEL: Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 …: https://t.co/XzHdz4Jeyb September 24th 2017, 9:09pm |
 |
@VisualStockRSRC $EXEL - Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone https://t.co/sCofyXea9A September 24th 2017, 9:09pm |
|
@newswithvalue $EXEL $INCY: 3 Monster Biotech Stocks in the Making: https://t.co/69jVxkC8kg September 24th 2017, 9:09am |
 |
@TickerReport Stelios Papadopoulos Sells 10,000 Shares of Exelixis, Inc. $EXEL Stock https://t.co/qQ6xuoHFmT September 24th 2017, 7:09am |
 |
@emq_news Stelios Papadopoulos Sells 10,000 Shares of Exelixis, Inc. $EXEL Stock https://t.co/z7ZdzCFOuZ September 24th 2017, 7:09am |
|
@TickerReport Stelios Papadopoulos Sells 10,000 Shares of Exelixis, Inc. $EXEL Stock https://t.co/jj103nqmmx September 24th 2017, 7:09am |
|
@emq_news Somewhat Positive Media Coverage Somewhat Unlikely to Affect Exelixis $EXEL Stock Price https://t.co/ttq1FXxnJ1 September 24th 2017, 4:09am |
|
@TickerReport Somewhat Positive Media Coverage Somewhat Unlikely to Affect Exelixis $EXEL Stock Price https://t.co/S5Czff5Kik September 24th 2017, 4:09am |
Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.